MannKind Corporation (MNKD)
NASDAQ: MNKDHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
MNKD stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.24B
- Forward P/E
- 24.44
- EPS (TTM)
- -$0.24
- Dividend yield
- None
- 52-week range
- 2.23 – 6.51
- Day range
- 3.83 – 4.08
- Volume / Avg
- 4.18M / 3.96M
- Beta
- —
- Shares outstanding
- 321.64M
52-week range
MNKD stock today
On Nov 20, MNKD ended the session at $3.85, shedding $0.10 (2.53%), versus the S&P 500's 3.70% decline. At this level, MNKD sits in the middle of its 52-week range of $2.23 to $6.51: 40.9% below the high, set on Jan 8, 2026 and 72.6% above the low. MNKD is down 32.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 23.5%.
MannKind has posted a net loss over the last twelve months (EPS of -$0.24), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About MannKind
Company profileMannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. The company's commercial products include Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes; Furoscix, a formulation of furosemide injection to treat edema in pediatric patients and adult patients with chronic heart failure or chronic kidney disease; and V-Go, a mechanical basal-bolus insulin delivery system, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Michael E. Castagna Pharm.D.
- Headquarters
- Danbury, CT
- Employees
- 591
- IPO year
- 2004
- Website
- mannkindcorp.com
Financial highlights
Full financialsIn fiscal 2025, MannKind generated $349.0 million in revenue, up 22.2% from fiscal 2024, its 8th consecutive year of revenue growth. Net income was $5.9 million (-78.7% year over year), for a net margin of 1.7% versus a median of -87.6% in the prior 5 years. Gross margin was 92.3% (down from 93.9%) and operating margin 11.1%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $348.97M | $285.50M | $198.96M | $99.77M | $75.44M |
| Growth | +22.23% | +43.50% | +99.42% | +32.25% | +15.81% |
| Net income | $5.86M | $27.59M | $-11.94M | $-87.40M | $-80.93M |
| EPS (diluted) | $0.02 | $0.10 | $-0.04 | $-0.34 | $-0.32 |
Analyst forecast
ForecastConsensus (9 analysts)
strong_buy
Avg. price target
$8.33+116.36%
- Strong buy 0
- Buy 8
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $0.03 vs $-0.08
- Surprise
- +137.50%
MNKD news
All MNKD news- MannKind to Participate in Upcoming Investor ConferencesGlobeNewswire
- MannKind (MNKD) Q3 2026 Earnings Call TranscriptNasdaq
- MannKind anticipates $1B in revenue from United Therapeutics deal from 2027-2030 as it targets Q4 profitabilitySeeking AlphaMNKD, UTHR
- MannKind Corporation Reports Third Quarter 2026 Financial ResultsNasdaq
- MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026GlobeNewswire
- MannKind to Participate in the Chardan Healthcare ConferenceGlobeNewswire
- MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)GlobeNewswire
MannKind peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SLNSilence Therapeutics Plc American Depository Share | 19.81 | 0.00% | $1.23B | vs MNKD |
| GENBGenerate Biomedicines Inc. | 9.54 | -8.00% | $1.23B | vs MNKD |
| OCULOcular Therapeutix Inc. | 5.57 | -4.95% | $1.23B | vs MNKD |
| LBRXLB Pharmaceuticals Inc | 38.85 | -2.97% | $1.26B | vs MNKD |
| AVLNAvalyn Pharma Inc. | 28.40 | -1.05% | $1.26B | vs MNKD |
| MLYSMineralys Therapeutics Inc. | 13.66 | -3.53% | $1.21B | vs MNKD |
| AMPHAmphastar Pharmaceuticals Inc. | 28.25 | +0.50% | $1.20B | vs MNKD |
| GHRSGH Research PLC | 17.53 | -5.55% | $1.20B | vs MNKD |
Indexes, lists and sector
MannKind stock FAQ
What is MannKind's stock price today?
MNKD last traded at $3.85 as of Nov 20, 4:00 PM EST, down 2.53% on the day. Prices are delayed at least 15 minutes.
Does MannKind pay a dividend?
No. MannKind does not currently pay a regular cash dividend.
Who is MannKind's CEO?
Dr. Michael E. Castagna Pharm.D. is the chief executive officer of MannKind Corporation, which has about 591 employees.
Has MNKD ever split its stock?
Yes. The most recent MNKD stock split was a 1-for-5 split on Mar 3, 2017.
What is the MNKD 52-week high?
The 52-week high for MNKD is $6.51 and the 52-week low is $2.23. The stock is currently 40.9% below its high.